Pratik S. Multani net worth and biography

Pratik Multani Biography and Net Worth

Chief Medical Officer of Oric Pharmaceuticals

Dr. Multani brings to ORIC^® more than 20 years of experience in oncology drug development and treatment of patients with cancer. Most recently, Dr. Multani served as Chief Medical Officer of Ignyta, which was acquired by Roche, where he led all development and regulatory activities related to multiple clinical stage assets, including Ignyta’s lead program entrectinib, which is currently approved in the United States and Japan.

Prior to Ignyta, Dr. Multani was Chief Medical Officer of Fate Therapeutics, and prior to that he held multiple leadership positions at Kalypsys, Kanisa and Salmedix. Dr. Multani started his biotech career at Biogen Idec, where he was involved with the development of both Zevalin^® and Rituxan^® for treatment of non-Hodgkin lymphoma.

Prior to his career in biotech, Dr. Multani held academic and clinical positions at Harvard Medical School and at Massachusetts General Hospital. His postdoctoral training included a fellowship in hematology and oncology at Dana-Farber/Partners and an internship and residency in internal medicine at Massachusetts General Hospital. Dr. Multani received an MD from Harvard Medical School and an MS in clinical epidemiology from Harvard School of Public Health. He currently serves on the board of directors of Erasca and Chimerix (NASDAQ: CMRX).

What is Pratik S. Multani's net worth?: The estimated net worth of Pratik S. Multani is at least $532.65 thousand as of December 16th, 2024. Dr. Multani owns 46,765 shares of Oric Pharmaceuticals stock worth more than $532,653 as of December 4th. This net worth evaluation does not reflect any other assets that Dr. Multani may own. Additionally, Dr. Multani receives an annual salary of $715,220.00 as Chief Medical Officer at Oric Pharmaceuticals. Learn More about Pratik S. Multani's net worth.
How old is Pratik S. Multani?: Dr. Multani is currently 57 years old. There are 7 older executives and no younger executives at Oric Pharmaceuticals. The oldest executive at Oric Pharmaceuticals is Dr. Richard A. Heyman Ph.D., Co-Founder, Independent Chairman & Member of Scientific Advisory Board, who is 67 years old. Learn More on Pratik S. Multani's age.
What is Pratik S. Multani's salary?: As the Chief Medical Officer of Oric Pharmaceuticals, Inc., Dr. Multani earns $715,220.00 per year. The highest earning executive at Oric Pharmaceuticals is Dr. Jacob M. Chacko M.B.A., M.D., President, CEO & Director, who commands a salary of $961,000.00 per year. Learn More on Pratik S. Multani's salary.
How do I contact Pratik S. Multani?: The corporate mailing address for Dr. Multani and other Oric Pharmaceuticals executives is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. Oric Pharmaceuticals can also be reached via phone at 650-388-5600 and via email at [email protected]. Learn More on Pratik S. Multani's contact information.
Has Pratik S. Multani been buying or selling shares of Oric Pharmaceuticals?: Pratik S. Multani has not been actively trading shares of Oric Pharmaceuticals during the last ninety days. Most recently, Pratik S. Multani sold 8,850 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $8.28, for a transaction totalling $73,278.00. Following the completion of the sale, the insider now directly owns 46,765 shares of the company's stock, valued at $387,214.20. Learn More on Pratik S. Multani's trading history.
Who are Oric Pharmaceuticals' active insiders?: Oric Pharmaceuticals' insider roster includes Jacob Chacko (CEO), Carl Gordon (Director), Richard Heyman (Director), Pratik Multani (Chief Medical Officer), Dominic Piscitelli (CFO), Richard Scheller (Director), and Angie You (Director). Learn More on Oric Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Oric Pharmaceuticals?: During the last twelve months, Oric Pharmaceuticals insiders bought shares 2 times. They purchased a total of 28,000 shares worth more than $262,976.12. During the last twelve months, insiders at the sold shares 15 times. They sold a total of 343,361 shares worth more than $3,791,740.79. The most recent insider tranaction occured on October, 6th when CFO Dominic Piscitelli sold 11,000 shares worth more than $159,720.00. Insiders at Oric Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Oric Pharmaceuticals.
Information on this page was last updated on 10/6/2025.

Pratik S. Multani Insider Trading History at Oric Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2024	Sell	8,850	$8.28	$73,278.00	46,765
12/15/2023	Sell	5,282	$8.59	$45,372.38	23,809
12/15/2022	Sell	2,089	$3.25	$6,789.25	7,423

Pratik S. Multani Buying and Selling Activity at Oric Pharmaceuticals

Oric Pharmaceuticals Company Overview

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Today's Range

Now: $11.39

$10.72

$11.54

50 Day Range

MA: $12.44

$10.65

$14.41

2 Week Range

Now: $11.39

$3.90

$14.93

Volume

1,266,442 shs

Average Volume

1,130,416 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Pratik Multani Biography and Net Worth

What is Pratik S. Multani's net worth?

How old is Pratik S. Multani?

What is Pratik S. Multani's salary?

How do I contact Pratik S. Multani?

Has Pratik S. Multani been buying or selling shares of Oric Pharmaceuticals?

Who are Oric Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Oric Pharmaceuticals?